My NCBISign In
Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy
Luigi Camporota, Eleonora Corno, Eleonora Menaldo, John Smith, Katie Lei, Richard Beale, Duncan Wyncoll
Crit Care. 2008; 12(6): R163. Published online 2008 December 18. doi: 10.1186/cc7163
PMCID:
PMC2646328
Abstract Full Text PDF–99K Supplementary Material

Is Cited by the Following 3 Articles in this Archive:

Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation
L Mirea, I Luca Vasiliu, R Ungureanu, A Balanescu, I Grintescu
Crit Care. 2011; 15(Suppl 1): P124. Published online 2011 March 11. doi: 10.1186/cc9544
PMCID:
PMC3061754
Full Text PDF–5.9M
Year in review 2008: Critical Care - nephrology
Zaccaria Ricci, Claudio Ronco
Crit Care. 2009; 13(5): 227. Published online 2009 October 21. doi: 10.1186/cc7961
PMCID:
PMC2784338
Abstract Full Text PDF–67K
Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis
Anne CJM de Pont, Marcus J Schultz
Crit Care. 2009; 13(1): 113. Published online 2009 February 2. doi: 10.1186/cc7684
PMCID:
PMC2688108
Abstract Full Text PDF–41K
You are here: NCBI > Literature > PubMed Central (PMC)
Write to the Help Desk